PH12015500915B1 - Uses of bremelanotide in therapy for female sexual dysfunction - Google Patents

Uses of bremelanotide in therapy for female sexual dysfunction Download PDF

Info

Publication number
PH12015500915B1
PH12015500915B1 PH12015500915A PH12015500915A PH12015500915B1 PH 12015500915 B1 PH12015500915 B1 PH 12015500915B1 PH 12015500915 A PH12015500915 A PH 12015500915A PH 12015500915 A PH12015500915 A PH 12015500915A PH 12015500915 B1 PH12015500915 B1 PH 12015500915B1
Authority
PH
Philippines
Prior art keywords
bremelanotide
peak plasma
plasma concentration
minutes
female
Prior art date
Application number
PH12015500915A
Other languages
English (en)
Other versions
PH12015500915A1 (en
Inventor
Carl Spana
Robert Jordan
Jeffrey D Edelson
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015500915(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of PH12015500915A1 publication Critical patent/PH12015500915A1/en
Publication of PH12015500915B1 publication Critical patent/PH12015500915B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
PH12015500915A 2012-11-05 2015-04-23 Uses of bremelanotide in therapy for female sexual dysfunction PH12015500915B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
PH12015500915A1 PH12015500915A1 (en) 2015-06-29
PH12015500915B1 true PH12015500915B1 (en) 2015-06-29

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015500915A PH12015500915B1 (en) 2012-11-05 2015-04-23 Uses of bremelanotide in therapy for female sexual dysfunction

Country Status (23)

Country Link
US (7) US9352013B2 (OSRAM)
EP (1) EP2916856B2 (OSRAM)
JP (1) JP6567971B2 (OSRAM)
KR (1) KR102253526B1 (OSRAM)
CN (2) CN117860866A (OSRAM)
AU (1) AU2013337341B2 (OSRAM)
BR (1) BR112015009936A8 (OSRAM)
DK (1) DK2916856T4 (OSRAM)
EA (1) EA032959B9 (OSRAM)
ES (1) ES2701444T5 (OSRAM)
FI (1) FI2916856T4 (OSRAM)
GE (2) GEP20196947B (OSRAM)
HK (1) HK1211227A1 (OSRAM)
IL (1) IL238276B (OSRAM)
MX (1) MX362610B (OSRAM)
MY (1) MY179755A (OSRAM)
NZ (1) NZ707246A (OSRAM)
PH (1) PH12015500915B1 (OSRAM)
PL (1) PL2916856T5 (OSRAM)
SG (1) SG11201502949QA (OSRAM)
UA (1) UA118656C2 (OSRAM)
WO (1) WO2014071339A2 (OSRAM)
ZA (1) ZA201503128B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1289587B1 (en) * 2000-05-31 2005-08-03 Novo Nordisk A/S A disposable double pointed injection needle
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
MX2007006973A (es) * 2004-12-09 2007-08-15 West Pharm Serv Inc Acoplamiento para un dispositivo de auto-inyeccion.
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
WO2009152079A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US9314509B2 (en) * 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
KR101850687B1 (ko) * 2010-04-21 2018-04-20 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스

Also Published As

Publication number Publication date
US10286034B2 (en) 2019-05-14
JP2016503406A (ja) 2016-02-04
US20140378392A1 (en) 2014-12-25
DK2916856T3 (en) 2019-01-14
SG11201502949QA (en) 2015-06-29
US20190216888A1 (en) 2019-07-18
GEAP201813826A (en) 2018-10-25
PL2916856T5 (pl) 2024-01-29
EP2916856A2 (en) 2015-09-16
MX2015005486A (es) 2015-11-13
CA2890081A1 (en) 2014-05-08
MX362610B (es) 2019-01-28
DK2916856T4 (da) 2024-01-22
JP6567971B2 (ja) 2019-08-28
FI2916856T4 (fi) 2024-01-15
BR112015009936A8 (pt) 2019-09-17
US20220362328A1 (en) 2022-11-17
EA032959B1 (ru) 2019-08-30
MY179755A (en) 2020-11-12
CN117860866A (zh) 2024-04-12
EA201590760A1 (ru) 2015-10-30
BR112015009936A2 (pt) 2017-07-11
US9700592B2 (en) 2017-07-11
US20150231196A1 (en) 2015-08-20
AU2013337341A1 (en) 2015-05-07
PH12015500915A1 (en) 2015-06-29
US20180085425A1 (en) 2018-03-29
IL238276A0 (en) 2015-06-30
US9352013B2 (en) 2016-05-31
GEP20196947B (en) 2019-02-11
ZA201503128B (en) 2016-11-30
ES2701444T5 (es) 2024-05-21
NZ707246A (en) 2019-03-29
EP2916856B2 (en) 2023-10-18
US20210060120A1 (en) 2021-03-04
KR20150081345A (ko) 2015-07-13
ES2701444T3 (es) 2019-02-22
WO2014071339A2 (en) 2014-05-08
IL238276B (en) 2020-04-30
US20240335502A1 (en) 2024-10-10
EA032959B9 (ru) 2019-11-27
HK1211227A1 (en) 2016-05-20
CN104755094A (zh) 2015-07-01
AU2013337341B2 (en) 2018-02-22
EP2916856A4 (en) 2016-06-22
UA118656C2 (uk) 2019-02-25
PL2916856T3 (pl) 2019-02-28
EP2916856B1 (en) 2018-09-19
KR102253526B1 (ko) 2021-05-18
WO2014071339A3 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
US20240335502A1 (en) Uses of bremelanotide in therapy for female sexual dysfunction
JP2020019790A (ja) プラダー・ウィリー症候群を治療する方法
JP2010530902A (ja) 流涎症治療のためのグリコピロレートを含む経皮送達システム
US12171807B2 (en) Use of bremelanotide in patients with controlled hypertension
KR20200022026A (ko) 치료 방법 및 이의 약형
CA2890081C (en) Uses of bremelanotide in therapy for female sexual dysfunction
HK40108156A (zh) 用於女性性功能障碍的布雷默浪丹疗法
EP4646204A1 (en) Compound for treatment of erectile dysfunction